SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers
hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases …

The ability of a virus to spread between individuals, its replication capacity and the clinical
course of the infection are macroscopic consequences of a multifaceted molecular …

Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay
between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro …

Although vaccines and monoclonal antibody countermeasures have reduced the morbidity
and mortality associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

A significant number of COVID‐19 patients were shown to have neutralizing antibodies
(NAB) against IFN; however, NAB specificity, fluctuation over time, associations with …

Severe acute respiratory disease coronavirus 2 (SARS-CoV-2) is responsible for the
coronavirus disease 2019 (COVID-19) pandemic. Although a primarily respiratory disease …

The COVID‐19 pandemic has represented an unprecedented challenge for the humanity,
and scientists around the world provided a huge effort to elucidate critical aspects in the fight …

Antiviral type I interferons (IFN) produced in the early phase of viral infections effectively
inhibit viral replication, prevent virus-mediated tissue damages and promote innate and …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an exceptionally
transmissible and pathogenic coronavirus that appeared at the end of 2019 and triggered a …

The new variant of concern (VOC) of SARS-CoV-2, Omicron (B. 1.1. 529), is genetically very
different from other VOCs. We compared Omicron with the preceding VOC Delta (B. 1.617 …